Akeso, Inc. (HKG:9926)

Market Cap	98.84B +88.2%
Revenue (ttm)	2.75B +34.0%
Net Income	-927.04M
EPS	-1.06
Shares Out	921.14M
PE Ratio	n/a
Forward PE	240.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,169,625
Average Volume	5,520,124
Open	100.50
Previous Close	102.00
Day's Range	99.60 - 107.70
52-Week Range	60.60 - 179.00
Beta	0.28
RSI	51.39
Earnings Date	Mar 16, 2026

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 3,529
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9926

Financial Performance

Financial numbers in CNY